Obesity care is entering a new chapter, with international guidance and medication research advancing on parallel tracks. This week, the World Health Organization (WHO) is launching new guidelines for children and adolescents, while scientists are investigating treatments that could expand options.
Together, these developments highlight the need for care that responds to individual needs, and evidence that establishes which treatments deliver meaningful, lasting benefits.
WHO addresses a gap in childhood obesity care
On October 7, 2026, WHO is scheduled to launch two guidelines on the integrated management of obesity in children and adolescents. The recommendations aim to help health systems and healthcare professionals provide timely, evidence-based care centered on the people receiving it. Alongside WHO’s existing adult recommendations, they will help establish a more complete framework for obesity management across the life course.
The need is substantial. According to WHO, an estimated 400 million children and adolescents ages 5-19 were overweight in 2024, including 170 million living with obesity. Obesity prevalence in this age group has quadrupled since 1990.
WHO’s virtual launch will introduce the recommendations and feature an expert discussion of the supporting evidence. Until that presentation and review of the final guidelines, the announcement should not be interpreted as endorsing particular medications or treatment approaches.
New medicines bring new research questions
A September 2026 scientific statement from the Endocrine Society examines the changing landscape of obesity medicines and the questions that remain unanswered. These include differences in treatment response, health outcomes beyond weight loss, and the long-term safety of current and emerging therapies.
In the Patient Care Online interview, Daniel J. Drucker, M.D., of the University of Toronto, discussed investigational retatrutide, amylin-based therapies, oral agents, and glucagon/GLP-1 combinations. The central issue is whether additional treatments can offer distinct benefits or help people whose needs are not adequately met by existing medicines.
Retatrutide illustrates both the potential and the uncertainty. It activates three hormone receptors: GIP, GLP-1, and glucagon. In a phase 2 trial of 338 adults, the highest studied dose produced an average weight reduction of 24.2% after 48 weeks, compared with 2.1% in the placebo group.
Those results support further investigation. They do not establish that retatrutide is safer or produces better health outcomes than approved obesity medicines. Because the trial involved adults, its findings also cannot establish benefits or safety for children and adolescents.
Dr. Drucker also emphasized the importance of a medicine’s approval status and source. Investigational products obtained outside regulated clinical trials should not be assumed equivalent to approved medicines.
Could obesity medicines have other uses?
Researchers are also exploring whether some obesity medicines could have applications beyond weight management, including substance use disorders. Reports of reduced interest in alcohol or tobacco have drawn attention, but individual experiences cannot establish a treatment’s effectiveness.
A small randomized trial involving 48 adults with alcohol use disorder found that nine weeks of semaglutide treatment reduced some measures of alcohol craving and drinking compared with placebo. However, the study’s limited size, short duration, and selected population mean that broader conclusions about clinical use require further research.
Building healthcare around stronger evidence
The WHO launch and the Endocrine Society statement serve different purposes: One introduces care recommendations for younger patients, while the other maps research priorities for obesity science. Their shared message is that progress requires more than promising weight-loss numbers. Understanding safety, individual treatment response, and broader health benefits will be essential to translating new discoveries into better care.
Your responses and feedback are welcome!
Source: “Launch of WHO guidelines: integrated management of obesity in children and adolescents,” WHO.int, 10/7/26
Source: “Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines,” PatientCareOnline.com, 9/29/26
Image by Pavel Danilyuk/Pexels
FAQs and Media Requests: 
